Exchange: NASDAQ·Updated 07:43 PM EDT
News
all
press releases
OCUL Stock In Spotlight After Q2 Loss Comes In Narrower Than Estimated – A Look At Key Highlights
Ocular’s total cash and cash equivalents stood at $598.6 million at the end of the second quarter, which it expects will provide sufficient cash runway until 2028.
Stocktwits
More News
Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of +12.50% and +6.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda?
Ocular said its U.S. Food and Drug Administration-aligned New Drug Application for wet age-related macular degeneration therapy is expected to be submitted in the fourth quarter of 2026.
Stocktwits
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsOcular Therapeutix is transitioning into a major player in the retinal disease market with its lead program, Axpaxli...
Nasdaq News: Markets
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1
Key PointsAcuta Capital Partners reduced its Ocular Therapeutix holding by 460,887 shares...
Nasdaq News: Markets
What This Fund's $14 Million Ocular Therapeutix Exit Could Signal for Investors
Key PointsSaturn V sold 1,504,880 shares of Ocular Therapeutix in the first quarter; the estimated transaction value was $14.34 million...
Nasdaq News: Markets
Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures down 0.1%, Dole PLC drops 5.9% after missing earning estimates, other stocks also decline in pre-market trading.read more...
Benzinga
Ocular Therapeutix (NASDAQ:OCUL) Receives "Outperform" Rating from Royal Bank Of Canada
Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $30.00 target price on shares of Ocular Therapeutix in a report on Wednesday...
MarketBeat
Ocular Therapeutix Q1 Earnings Call Highlights
Ocular Therapeutix (NASDAQ:OCUL) management used its first-quarter 2026 earnings call to highlight clinical and regulatory progress for AXPAXLI, the company's investigational therapy for wet...
MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS
Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) announced its earnings results on Tuesday. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The firm had revenue of $10.79 million for the quarter...
MarketBeat

Advertisement|Remove ads.